Anti-alpha-actinin Antibodies and Lupus Nephritis Activity

Lupus nephritis (LN) develops in 30-60% of systemic lupus erythematosus (SLE) patients and remains a leading cause of morbidity, with 10-30% progressing to end-stage renal disease within 15 years. The International Society of Nephrology/Renal Pathology Society (ISN/RPS) classifies LN histologically, with proliferative forms (Classes III/IV) carrying the poorest prognosis.

NCT Number	NCT07505576
Lead Sponsor	Assiut University
Conditions	Lupus Nephritis
Enrollment	96 participants
Start Date	2026-04-01
Primary Completion	2027-04-01 (estimated)
Study Completion	2027-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-01